Ohio State University Comprehensive Cancer Center
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.cancer.osu.edu
Clinical Trials
334
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (293 trials with phase data)β’ Click on a phase to view related trials
Strategies for Optimizing a Mailed FIT Program in Appalachia
- Conditions
- Colonic Neoplasms
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-19
- Target Recruit Count
- 500
- Registration Number
- NCT07173985
- Locations
- πΊπΈ
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
- Conditions
- Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveRecurrent Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Chronic Myeloid Leukemia, BCR-ABL1 PositiveRecurrent Indolent Non-Hodgkin LymphomaRecurrent Lymphoblastic LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Acute Lymphoblastic LeukemiaRefractory Chronic Lymphocytic Leukemia
- Interventions
- Biological: Autologous Anti-CD19/CD20/CD22 CAR T-cellsProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Multigated Acquisition ScanProcedure: PheresisProcedure: Positron Emission Tomography
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Target Recruit Count
- 24
- Registration Number
- NCT07166419
- Locations
- πΊπΈ
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
- Conditions
- Advanced Ovarian CarcinomaRecurrent Ovarian CarcinomaStage II Ovarian Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionDietary Supplement: ProbioticDrug: Placebo AdministrationOther: Questionnaire Administration
- First Posted Date
- 2025-08-28
- Last Posted Date
- 2025-08-28
- Target Recruit Count
- 161
- Registration Number
- NCT07144826
- Locations
- πΊπΈ
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer
- Conditions
- Localized Pancreatic Ductal AdenocarcinomaStage 0 Pancreatic Cancer AJCC v8Stage I Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-08-15
- Target Recruit Count
- 25
- Registration Number
- NCT07124611
- Locations
- πΊπΈ
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Studying Flavors and Cooling Agents in Oral Nicotine Pouches to Understand User Preferences
- Conditions
- Cigarette Smoking-Related Carcinoma
- Interventions
- Procedure: Carbon Monoxide MeasurementOther: Questionnaire AdministrationDrug: Smoke usual brand cigarette
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-09-15
- Target Recruit Count
- 30
- Registration Number
- NCT07111234
- Locations
- πΊπΈ
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 67
- Next
News
TAE Life Sciences and Ohio State University Partner to Advance Boron Neutron Capture Therapy for Cancer Treatment
TAE Life Sciences and Ohio State University have formed the first U.S.-based academic-industry alliance focused on developing novel boron-based drug compounds for Boron Neutron Capture Therapy (BNCT).
ACCC Fall 2024: Innovations in Clinical Trial Access, Patient Care, and Treatment Authorization
The Ohio State University Cancer Center's automated informatics program has achieved a 21.9% increase in biosimilar utilization while streamlining prior authorization processes, earning an Innovator Award at ACCC 2024.
First-in-Human Trial Launched for Novel DHODH Inhibitor HOSU-53 in Solid Tumors and Lymphomas
A Phase I/II clinical trial is set to begin at Ohio State University, evaluating the novel DHODH inhibitor HOSU-53 in patients with advanced solid tumors and Non-Hodgkin's lymphoma.
Nanopharmaceutics Completes Enrollment in Phase 2 Neuroendocrine Tumor Study Combining Triapine with Lutetium Lu 177 Dotatate
Nanopharmaceutics has completed patient enrollment in a 94-patient Phase 2 randomized controlled trial evaluating Triapine plus lutetium Lu 177 dotatate versus standard therapy alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors.